PT3207053T - Novos péptidos imunogénicos - Google Patents
Novos péptidos imunogénicosInfo
- Publication number
- PT3207053T PT3207053T PT157879172T PT15787917T PT3207053T PT 3207053 T PT3207053 T PT 3207053T PT 157879172 T PT157879172 T PT 157879172T PT 15787917 T PT15787917 T PT 15787917T PT 3207053 T PT3207053 T PT 3207053T
- Authority
- PT
- Portugal
- Prior art keywords
- immunogenic peptides
- novel immunogenic
- novel
- peptides
- immunogenic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Rehabilitation Therapy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1418433.7A GB201418433D0 (en) | 2014-10-17 | 2014-10-17 | Novel immunogenic peptides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3207053T true PT3207053T (pt) | 2019-11-15 |
Family
ID=52013133
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT157879172T PT3207053T (pt) | 2014-10-17 | 2015-10-16 | Novos péptidos imunogénicos |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US20180228912A1 (enExample) |
| EP (2) | EP3207053B1 (enExample) |
| JP (2) | JP6655626B2 (enExample) |
| KR (1) | KR102556485B1 (enExample) |
| CN (1) | CN107148427B (enExample) |
| AU (2) | AU2015332621B2 (enExample) |
| BR (1) | BR112017007773A2 (enExample) |
| CA (1) | CA2964426C (enExample) |
| DK (1) | DK3207053T3 (enExample) |
| ES (1) | ES2751605T3 (enExample) |
| GB (1) | GB201418433D0 (enExample) |
| MX (1) | MX374635B (enExample) |
| PL (1) | PL3207053T3 (enExample) |
| PT (1) | PT3207053T (enExample) |
| RU (1) | RU2709711C2 (enExample) |
| WO (1) | WO2016059236A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2709176T3 (es) | 2006-08-11 | 2019-04-15 | Life Sciences Res Partners Vzw | Péptidos inmunogénicos y su uso en trastornos inmunitarios |
| EP2247306B1 (en) | 2008-02-14 | 2018-04-18 | Life Sciences Research Partners VZW | Immunogenic control of tumours and tumour cells |
| EP2719396B1 (en) | 2008-02-14 | 2017-06-21 | Life Sciences Research Partners VZW | Immunotherapy targeting intracellular pathogens |
| ES2869155T3 (es) | 2010-11-25 | 2021-10-25 | Imnate Sarl | Péptidos inmunogénicos para su uso en la prevención y/o tratamiento de enfermedades infecciosas, enfermedades autoinmunitarias, respuestas inmunitarias a alofactores, enfermedades alérgicas, tumores, rechazo de injerto y respuestas inmunitarias contra vectores virales usados para terapia génica o vacunación génica |
| GB201201511D0 (en) | 2012-01-30 | 2012-03-14 | Univ Leuven Kath | Modified epitopes for boosting CD4+ T-cell responses |
| GB201309469D0 (en) | 2013-05-28 | 2013-07-10 | Imcyse Sa | Detection of CD4+ T lymphocytes |
| GB201418433D0 (en) * | 2014-10-17 | 2014-12-03 | Imcyse Sa | Novel immunogenic peptides |
| US10729791B2 (en) | 2015-05-18 | 2020-08-04 | Imcyse Sa | Animal models for evaluating pharmaceutical compounds |
| WO2019113342A1 (en) | 2017-12-07 | 2019-06-13 | Sanford Burnham Prebys Medical Discovery Institute | Compositions and methods for treating nervous system injuries |
| WO2017040976A1 (en) | 2015-09-02 | 2017-03-09 | Erkki Ruoslahti | Compounds and compositions for targeting brain injuries and methods of use thereof |
| EP3352782B1 (en) | 2015-09-25 | 2021-03-31 | ImCyse SA | Improved methods and compounds for eliminating immune responses to therapeutic agents |
| KR20220132023A (ko) | 2016-04-19 | 2022-09-29 | 임시스 에스에이 | 신규 면역원성 CD1d 결합 펩티드 |
| SG11201908275XA (en) * | 2017-03-09 | 2019-10-30 | Imcyse Sa | Peptides and methods for the treatment of diabetes |
| US20210401976A1 (en) * | 2018-11-12 | 2021-12-30 | Imcyse Sa | Immunogenic peptides with improved oxidoreductase motifs |
| CA3138713A1 (en) | 2019-05-16 | 2020-11-19 | Imcyse Sa | Immunogenic peptides with an oxidoreductase motif comprising a modified cysteine |
| CN114746111A (zh) | 2019-11-27 | 2022-07-12 | 易姆赛斯股份公司 | 用于对糖尿病患者进行分层的方法 |
| CU20220066A7 (es) | 2020-05-06 | 2023-06-13 | Imcyse Sa | Péptidos inmunogénicos útiles en el tratamiento de esclerosis múltiple |
| AU2021266401A1 (en) | 2020-05-06 | 2022-12-15 | Imcyse Sa | Immunogenic peptides with new oxidoreductase motifs |
| JP2023525276A (ja) * | 2020-05-06 | 2023-06-15 | アンシス・エスア | 延長された酸化還元酵素モチーフを有する免疫原性ペプチド |
| EP4146190A2 (en) * | 2020-05-06 | 2023-03-15 | Imcyse SA | Combination treatment for fumarate-related diseases |
| EP3915575A1 (en) * | 2020-05-29 | 2021-12-01 | Imnate Sarl | Vaccine formulations |
| EP4321528A4 (en) * | 2021-04-09 | 2025-04-30 | Ajou University Industry-Academic Cooperation Foundation | PEPTIDE FOR THE PREVENTION OR TREATMENT OF INFLAMMATORY DISEASES |
| BR112023024116A2 (pt) | 2021-05-26 | 2024-02-06 | Imcyse Sa | Métodos de tratamento ou prevenção de doenças autoimunes |
| PH12023553212A1 (en) | 2021-06-01 | 2024-02-19 | Imcyse Sa | Improved methods of treatment using immunogenic peptides |
| WO2022256637A2 (en) * | 2021-06-03 | 2022-12-08 | David Weiner | Synthetic dna vaccine immunogenic improvements |
| AR126654A1 (es) | 2021-06-29 | 2023-11-01 | Imcyse Sa | Péptidos y métodos para el tratamiento de neuromielitis óptica |
Family Cites Families (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4599231A (en) | 1984-03-09 | 1986-07-08 | Scripps Clinic And Research Foundation | Synthetic hepatitis B virus vaccine including both T cell and B cell determinants |
| US4886782A (en) | 1987-02-26 | 1989-12-12 | The United States Of America As Represented By The Department Of Health And Human Services | Malarial immunogen |
| US5433948A (en) | 1990-02-13 | 1995-07-18 | Thomas; Wayne R. | Cloning and sequencing of allergens of dermatophagoides (house dust mite) |
| AU650911B2 (en) | 1990-09-27 | 1994-07-07 | Syntello Vaccine Development Kb | Peptides for use in vaccination and induction of neutralizing antibodies against human immunodeficiency virus |
| US7252829B1 (en) | 1998-06-17 | 2007-08-07 | Idm Pharma, Inc. | HLA binding peptides and their uses |
| US5589582A (en) | 1992-10-27 | 1996-12-31 | Biotransplant, Inc. | Polynucleotides en coding porcine cytokines |
| US5633234A (en) | 1993-01-22 | 1997-05-27 | The Johns Hopkins University | Lysosomal targeting of immunogens |
| JP3926839B2 (ja) | 1993-09-14 | 2007-06-06 | エピミューン，インコーポレイティド | 万能ｄｒ−結合性ペプチドを用いる免疫応答の改変 |
| US8791237B2 (en) | 1994-11-08 | 2014-07-29 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treatment of non-hodgkins lymphoma |
| US7157089B1 (en) | 1996-11-26 | 2007-01-02 | Stressgen Biotechnologies Corporation | Immune responses using compositions containing stress proteins |
| AU1124499A (en) | 1997-10-28 | 1999-05-17 | Maxygen, Inc. | Human papillomavirus vectors |
| NO315238B1 (no) | 1998-05-08 | 2003-08-04 | Gemvax As | Peptider som stammer fra leserammeforskyvingsmutasjoner i TBF<beta>II- eller BAX-genet, og farmasöytiske sammensetninger inneholdende disse,nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slikenukleinsy |
| US20030152581A1 (en) | 1998-07-30 | 2003-08-14 | Jean-Marie Saint-Remy | Compound and method for the prevention and/or the treatment of allergy |
| AR020102A1 (es) | 1998-07-30 | 2002-04-10 | Ucb Sa | Compuesto para la prevencion y/o tratamiento de la alergia; composicion farmaceutica, composicion cosmetica, composicion en forma de bebida, alimento y/oalimento para animales domesticos que lo comprende y uso de dicho compuesto o dicha composicion farmaceutica para la fabricacion de un alimento |
| HK1044040A1 (zh) | 1998-11-16 | 2002-10-04 | 德克萨斯州立大学董事会 | Hiv-特异的t-细胞诱导 |
| US7780882B2 (en) | 1999-02-22 | 2010-08-24 | Georgetown University | Simplified and improved method for preparing an antibody or an antibody fragment targeted immunoliposome for systemic administration of a therapeutic or diagnostic agent |
| EP2311951A1 (en) | 2000-01-28 | 2011-04-20 | The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services | Novel MHC class II restricted T cell epitopes from the cancer antigen, NY ESO-1 |
| GB0006437D0 (en) | 2000-03-17 | 2000-05-10 | Leuven Res & Dev Vzw | Compounds for the modulation of allergen sensitivity by antigens sharing T cell epitopes with allergens |
| EP1294905A1 (en) | 2000-06-26 | 2003-03-26 | SmithKline Beecham Biologics SA | Triple fusion proteins comprising ubiquitin fused between thioredoxin and a polypeptide of interest |
| US7049413B2 (en) | 2001-05-18 | 2006-05-23 | Ludwig Institute For Cancer Research | MAGE-A3 peptides presented by HLA class II molecules |
| EP1409650B1 (en) | 2001-05-30 | 2006-04-12 | Fondazione Telethon | Ex-vivo isolated cd25+cd4+ t cells with immunosuppressive activity and uses thereof |
| CA2458392A1 (en) | 2001-10-03 | 2003-04-17 | Unilever Plc | Carbohydrate binding domain containing fusion proteins for delivery of therapeutic and other agents, and compositions containing them |
| US20100183652A1 (en) | 2002-02-21 | 2010-07-22 | Mark Page | STABILIZED HBc CHIMER PARTICLES AS THERAPEUTIC VACCINE FOR CHRONIC HEPATITIS |
| AU2003215395A1 (en) | 2002-02-21 | 2003-09-09 | Apovia, Inc. | STABILIZED HBc CHIMER PARTICLES HAVING MENINGOCCOCAL IMMUNOGENS |
| DK2261249T3 (en) | 2002-09-12 | 2015-02-16 | Oncotherapy Science Inc | KDR peptides and vaccines comprising the same |
| WO2005012502A2 (en) | 2003-03-28 | 2005-02-10 | Idm Pharma, Inc. | Methods of identifying optimal variants of peptide epitopes |
| US7651855B2 (en) | 2003-04-17 | 2010-01-26 | The Trustees Of The University Of Pennsylvania | Regulatory T cells and their use in immunotherapy and suppression of autoimmune responses |
| EP1670509A4 (en) | 2003-09-03 | 2007-10-31 | Dendritherapeutics Inc | MULTIPLEX VACCINES |
| GB0324265D0 (en) | 2003-10-16 | 2003-11-19 | Medical Res Council | Peptide |
| US20070184023A1 (en) | 2003-10-30 | 2007-08-09 | Pharmexa A/S | Method for down-regulation of vegf |
| KR20070056042A (ko) | 2004-06-17 | 2007-05-31 | 맨카인드 코포레이션 | 에피토프 유사체 |
| US8252893B2 (en) | 2005-01-31 | 2012-08-28 | Board Of Trustees Of The University Of Arkansas | CD8 T cell epitopes in HPV 16 E6 and E7 proteins and uses thereof |
| WO2007027954A2 (en) | 2005-08-30 | 2007-03-08 | Children's Hospital & Research Center At Oakland | Methods for identifying an epitope of a polypeptide, chlamydial antigenic polypeptides identified thereby, and methods of use thereof |
| US10183986B2 (en) | 2005-12-15 | 2019-01-22 | Industrial Technology Research Institute | Trimeric collagen scaffold antibodies |
| GB0603081D0 (en) | 2006-02-15 | 2006-03-29 | Dynal Biotech Asa Oslo | Method |
| WO2007135684A2 (en) | 2006-05-22 | 2007-11-29 | Hadasit Medical Research Services & Development Limited | Method of treatment of anti-cd4 autoimmunity |
| ES2709176T3 (es) | 2006-08-11 | 2019-04-15 | Life Sciences Res Partners Vzw | Péptidos inmunogénicos y su uso en trastornos inmunitarios |
| WO2008145400A2 (en) | 2007-05-31 | 2008-12-04 | Medigene Ag | Mutated structural protein of a parvovirus |
| US8546137B2 (en) | 2007-09-27 | 2013-10-01 | The Board Of Trustees Of The University Of Arkansas | Inhibition of dendritic cell-driven regulatory T cell activation and potentiation of tumor antigen-specific T cell responses by interleukin-15 and MAP kinase inhibitor |
| EP2050814A1 (en) * | 2007-10-17 | 2009-04-22 | Txcell | Compositions for treating multiple sclerosis |
| EP2247306B1 (en) | 2008-02-14 | 2018-04-18 | Life Sciences Research Partners VZW | Immunogenic control of tumours and tumour cells |
| US20100330088A1 (en) | 2008-02-14 | 2010-12-30 | Jean-Marie Saint-Remy | Strategies to prevent and/or treat immunie responses to soluble allofactors |
| CA2715517C (en) | 2008-02-14 | 2018-07-24 | Life Sciences Research Partners Vzw | Immunogenic peptides and their use in preventing or treating allograft rejection |
| EP2719396B1 (en) | 2008-02-14 | 2017-06-21 | Life Sciences Research Partners VZW | Immunotherapy targeting intracellular pathogens |
| CA2715484C (en) | 2008-02-14 | 2017-04-11 | Life Sciences Research Partners Vzw | Suppression of immune responses to viral vectors |
| AU2009214041A1 (en) | 2008-02-14 | 2009-08-20 | Katholieke Universiteit Leuven | CD4+ T-cells with cytolytic properties |
| EP2254592B1 (en) | 2008-02-28 | 2019-06-05 | Dako Denmark A/S | Mhc multimers in borrelia diagnostics and disease |
| KR101022649B1 (ko) | 2008-08-07 | 2011-03-22 | 삼성모바일디스플레이주식회사 | 헤테로고리 화합물 및 이를 이용한 유기 전계 발광 장치 |
| RU2016137258A (ru) | 2009-04-01 | 2018-12-13 | Юниверсити Оф Майами | Композиции вакцин и способы их применения |
| WO2011120994A1 (en) | 2010-03-29 | 2011-10-06 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Pharmaceutical compositions comprising a polypeptide comprising at least one cxxc motif and heterologous antigens and uses thereof |
| ES2869155T3 (es) * | 2010-11-25 | 2021-10-25 | Imnate Sarl | Péptidos inmunogénicos para su uso en la prevención y/o tratamiento de enfermedades infecciosas, enfermedades autoinmunitarias, respuestas inmunitarias a alofactores, enfermedades alérgicas, tumores, rechazo de injerto y respuestas inmunitarias contra vectores virales usados para terapia génica o vacunación génica |
| GB201201511D0 (en) * | 2012-01-30 | 2012-03-14 | Univ Leuven Kath | Modified epitopes for boosting CD4+ T-cell responses |
| NZ722352A (en) | 2012-02-15 | 2022-05-27 | Ecole Polytechnique Fed Lausanne Epfl | Erythrocyte-binding therapeutics |
| EP2844741A1 (en) * | 2012-04-30 | 2015-03-11 | ImCyse SA | Methods for induction of antigen-specific regulatory t cells |
| GB201309469D0 (en) | 2013-05-28 | 2013-07-10 | Imcyse Sa | Detection of CD4+ T lymphocytes |
| GB201319160D0 (en) | 2013-10-30 | 2013-12-11 | Imcyse Sa | Methods for induction of antigen-specific regulatory t cells |
| JP2017500285A (ja) | 2013-11-04 | 2017-01-05 | ユーティーアイ リミテッド パートナーシップ | 持続的免疫療法のための方法および組成物 |
| GB201418433D0 (en) | 2014-10-17 | 2014-12-03 | Imcyse Sa | Novel immunogenic peptides |
| US10729791B2 (en) | 2015-05-18 | 2020-08-04 | Imcyse Sa | Animal models for evaluating pharmaceutical compounds |
| EP3352782B1 (en) | 2015-09-25 | 2021-03-31 | ImCyse SA | Improved methods and compounds for eliminating immune responses to therapeutic agents |
| KR20220132023A (ko) | 2016-04-19 | 2022-09-29 | 임시스 에스에이 | 신규 면역원성 CD1d 결합 펩티드 |
| SG11201908275XA (en) | 2017-03-09 | 2019-10-30 | Imcyse Sa | Peptides and methods for the treatment of diabetes |
| US20210401976A1 (en) | 2018-11-12 | 2021-12-30 | Imcyse Sa | Immunogenic peptides with improved oxidoreductase motifs |
| CA3138713A1 (en) | 2019-05-16 | 2020-11-19 | Imcyse Sa | Immunogenic peptides with an oxidoreductase motif comprising a modified cysteine |
-
2014
- 2014-10-17 GB GBGB1418433.7A patent/GB201418433D0/en not_active Ceased
-
2015
- 2015-10-16 BR BR112017007773-6A patent/BR112017007773A2/pt active Search and Examination
- 2015-10-16 WO PCT/EP2015/074063 patent/WO2016059236A1/en not_active Ceased
- 2015-10-16 EP EP15787917.2A patent/EP3207053B1/en active Active
- 2015-10-16 CN CN201580056434.6A patent/CN107148427B/zh active Active
- 2015-10-16 AU AU2015332621A patent/AU2015332621B2/en active Active
- 2015-10-16 PL PL15787917T patent/PL3207053T3/pl unknown
- 2015-10-16 ES ES15787917T patent/ES2751605T3/es active Active
- 2015-10-16 RU RU2017111657A patent/RU2709711C2/ru active
- 2015-10-16 KR KR1020177012944A patent/KR102556485B1/ko active Active
- 2015-10-16 CA CA2964426A patent/CA2964426C/en active Active
- 2015-10-16 PT PT157879172T patent/PT3207053T/pt unknown
- 2015-10-16 DK DK15787917T patent/DK3207053T3/da active
- 2015-10-16 JP JP2017540316A patent/JP6655626B2/ja active Active
- 2015-10-16 US US15/516,045 patent/US20180228912A1/en not_active Abandoned
- 2015-10-16 EP EP19192582.5A patent/EP3636666A1/en not_active Withdrawn
- 2015-10-16 MX MX2017004780A patent/MX374635B/es active IP Right Grant
-
2019
- 2019-10-17 AU AU2019250206A patent/AU2019250206A1/en not_active Abandoned
-
2020
- 2020-02-03 JP JP2020016331A patent/JP2020079271A/ja active Pending
- 2020-06-04 US US16/892,588 patent/US12023384B2/en active Active
-
2024
- 2024-05-24 US US18/674,092 patent/US20240342297A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20240342297A1 (en) | 2024-10-17 |
| AU2015332621A1 (en) | 2017-04-13 |
| ES2751605T3 (es) | 2020-04-01 |
| KR102556485B1 (ko) | 2023-07-17 |
| RU2017111657A3 (enExample) | 2019-05-29 |
| US20180228912A1 (en) | 2018-08-16 |
| CA2964426A1 (en) | 2016-04-21 |
| EP3636666A1 (en) | 2020-04-15 |
| WO2016059236A1 (en) | 2016-04-21 |
| JP2018504419A (ja) | 2018-02-15 |
| EP3207053B1 (en) | 2019-08-21 |
| JP2020079271A (ja) | 2020-05-28 |
| AU2019250206A1 (en) | 2019-11-07 |
| DK3207053T3 (da) | 2019-11-04 |
| RU2017111657A (ru) | 2018-11-19 |
| CN107148427B (zh) | 2021-08-13 |
| JP6655626B2 (ja) | 2020-02-26 |
| US12023384B2 (en) | 2024-07-02 |
| BR112017007773A2 (pt) | 2018-01-16 |
| GB201418433D0 (en) | 2014-12-03 |
| EP3207053A1 (en) | 2017-08-23 |
| RU2709711C2 (ru) | 2019-12-19 |
| CN107148427A (zh) | 2017-09-08 |
| US20200397911A1 (en) | 2020-12-24 |
| CA2964426C (en) | 2023-01-24 |
| PL3207053T3 (pl) | 2020-05-18 |
| KR20170069266A (ko) | 2017-06-20 |
| MX374635B (es) | 2025-03-06 |
| AU2015332621B2 (en) | 2019-07-18 |
| MX2017004780A (es) | 2017-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL3207053T3 (pl) | Nowe peptydy immunogenne | |
| GB201410971D0 (en) | Vaccine | |
| GB201518684D0 (en) | Vaccine | |
| ES2648672T5 (en) | Improved hvt-vectored nd-ibd vaccine | |
| GB201508337D0 (en) | Novel peptides | |
| GB201418562D0 (en) | Peptides | |
| GB201617324D0 (en) | Vaccine compositions | |
| GB201522132D0 (en) | Vaccine | |
| GB201401877D0 (en) | Peptides | |
| GB201616904D0 (en) | Vaccine | |
| GB201503483D0 (en) | Novel Antimmicrobial Peptides | |
| PL3188755T3 (pl) | Szczepionka | |
| GB201603029D0 (en) | Vaccine | |
| GB201410686D0 (en) | Peptides | |
| GB201417214D0 (en) | Vaccine | |
| GB201406628D0 (en) | Vaccine | |
| GB201408629D0 (en) | Novel peptides | |
| GB201420645D0 (en) | Peptides | |
| GB201412731D0 (en) | Peptides | |
| GB201409010D0 (en) | Peptides | |
| GB201405078D0 (en) | Peptides | |
| GB201614387D0 (en) | Improved vaccines | |
| GB201415235D0 (en) | Trans-locating peptide | |
| GB201518917D0 (en) | Vaccination | |
| GB201404910D0 (en) | Trans-locating peptide |